How is zotuximab used with chemotherapy? What is the combination treatment option?

VYLOY (Zolbetuximab) is an antibody that targets CLDN18.2 and is primarily used to treat gastric cancer and gastroesophageal junction cancer. CLDN18.2 is one of the common intercellular junction proteins in gastric cancer cells. It is usually expressed in normal gastric gland cells, but is highly expressed in a variety of gastric cancer tissues. Therefore, zotuximab blocks the growth and spread of tumor cells by targeting CLDN18.2 of these tumor cells, demonstrating its unique anti-tumor effect.

Combination chemotherapy treatment options

Based on clinical trials and research results, VYLOY (zotuximab) is often used in combination with chemotherapy drugs to improve their efficacy, especially in the treatment of patients with advanced gastric cancer. A common combination treatment regimen combines zotuximab with chemotherapy drugs such as 5-FU or oxaliplatin. These drug combinations have shown good inhibitory effects on gastric cancer cells in clinical trials, especially in the local progression or metastasis stage of cancer.

For example, a standard combination regimen might include biweekly dosing of zotuximab in combination with oxaliplatin or fluorouracil. As a targeted therapy drug, zotuximab can significantly enhance the anti-tumor effect and may reduce the drug resistance of cancer cells when combined with traditional chemotherapy drugs.

Clinical effects and research results

Currently, multiple clinical studies have achieved positive results on the effect of combining zotuximab with chemotherapy. For example, in a phase 3 clinical trial, gastric cancer patients treated with zotuximab in combination with chemotherapy showed more significant survival prolongation and tumor control effects than chemotherapy drugs alone. After patients received this combination treatment, overall survival, progression-free survival (PFS) and treatment response rate were significantly improved.

It is worth noting that zotuximab can not only enhance the killing effect of chemotherapy drugs on cancer cells, but also further enhance the anti-tumor effect of the immune system by targetingCLDN18.2. This combination therapy has shown great potential in the clinical treatment of gastric cancer, especially for patients who have received other treatments but failed to respond.

Side effects and management

Although zotuximab has shown good therapeutic effects in combination chemotherapy, certain adverse reactions may also occur. Common adverse reactions include fatigue, nausea, vomiting, gastrointestinal discomfort, etc. These symptoms are mainly caused by chemotherapy drugs. In addition, zotuximab may also cause immune-related side effects, such as rash, abnormal immune system reactions, etc. In order to maximize the therapeutic effect and reduce side effects, patients need to undergo regular physical examinations and laboratory tests under the guidance of a doctor to ensure that adverse reactions are monitored and managed in a timely manner.

During the combined treatment process, doctors will adjust the dosage of chemotherapy drugs according to the individual differences of the patient to ensure that the patient can benefit from the treatment to the maximum extent while reducing the occurrence of adverse reactions. Patients also need to work closely with their doctor to ensure that any side effects during treatment are managed and dealt with promptly.

VYLOYThe combination of VYLOY (zotuximab) and chemotherapy is an emerging treatment for gastric cancer, especially for patients with advanced or metastatic gastric cancer for whom traditional chemotherapy is ineffective. By targeting CLDN18.2 and combining it with traditional chemotherapy drugs, zotuximab can effectively improve tumor control rates and improve patients' survival expectations. Although combination therapy may cause some side effects, they can be effectively managed under a doctor's supervision. With further research, zotuximab combined with chemotherapy may become an important treatment option in the treatment of gastric cancer.

Reference materials:https://www.astellas.com/en/news/29401